Acute myeloid leukemia (AML) was one of the first cancers to be sequenced at the level of
the whole genome. Molecular profiling of AML through targeted sequencing panels and
cytogenetics has become a mainstay in risk-stratifying AML patients and guiding clinicians
toward optimal therapies for their patients. The extensive high-resolution genomic data
generated to characterize AML have been instrumental in revealing the tremendous
biological complexity of the disease, dictated in part by mutational, clonal, and epigenetic …